{"id":34522,"date":"2012-10-06T17:12:07","date_gmt":"2012-10-06T17:12:07","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com\/"},"modified":"2024-08-17T19:35:04","modified_gmt":"2024-08-17T23:35:04","slug":"trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/multiple-sclerosis\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com-2.php","title":{"rendered":"Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com"},"content":{"rendered":"<p><p>    New in-demand report \"Therapy Trends: Multiple Sclerosis -- KOL Insight and    Consensus Outlook Modules\" developed by FirstWord has been    recently published by Market Publishers Ltd. The report    states that the most recent clinical trials of a new multiple sclerosis    therapy were launched in Canada.  <\/p>\n<p>    London, UK (PRWEB) October 02, 2012  <\/p>\n<p>    Besides, new therapies are invented. For instance, the most    recent clinical trials of a new therapy were launched in late    September 2012 in Canada.  <\/p>\n<p>    New in-demand report \"Therapy Trends: Multiple    Sclerosis -- KOL Insight and Consensus Outlook Modules\"    developed by FirstWord has been recently published by    Market Publishers    Ltd.  <\/p>\n<p>    Report Details:  <\/p>\n<p>    Title: Therapy Trends: Multiple Sclerosis -- KOL Insight and    Consensus Outlook Modules  <\/p>\n<p>        Published: September, 2012  <\/p>\n<p>        Price: US$ 7,495.00 <a href=\"http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html\" rel=\"nofollow\">http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html<\/a>  <\/p>\n<p>    The report provides a comprehensive guide to trends in multiple    sclerosis therapy. It covers historical sales from 2006 through    2011, market majors and drug developers. The study includes    valuable data on current and late-stage pipeline drugs,    comparative clinical trial results. Sales outlook to 2016,    product positioning forecast, market growth expectations as    well as future event mapping can also be found in the research.  <\/p>\n<p>    Report Contents:  <\/p>\n<\/p>\n<p>More here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/news.yahoo.com\/trends-multiple-sclerosis-therapy-examined-insightful-firstword-report-175621290.html;_ylt=A2KJjalWZnBQdioAnWP_wgt.\" title=\"Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com\" rel=\"noopener\">Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> New in-demand report \"Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules\" developed by FirstWord has been recently published by Market Publishers Ltd. The report states that the most recent clinical trials of a new multiple sclerosis therapy were launched in Canada. London, UK (PRWEB) October 02, 2012 Besides, new therapies are invented. For instance, the most recent clinical trials of a new therapy were launched in late September 2012 in Canada. New in-demand report \"Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules\" developed by FirstWord has been recently published by Market Publishers Ltd. Report Details: Title: Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules Published: September, 2012 Price: US$ 7,495.00 <a href=\"http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html\" rel=\"nofollow\">http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html<\/a> The report provides a comprehensive guide to trends in multiple sclerosis therapy. It covers historical sales from 2006 through 2011, market majors and drug developers. The study includes valuable data on current and late-stage pipeline drugs, comparative clinical trial results. Sales outlook to 2016, product positioning forecast, market growth expectations as well as future event mapping can also be found in the research. Report Contents:  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/multiple-sclerosis\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246866],"tags":[],"class_list":["post-34522","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/34522"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=34522"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/34522\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=34522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=34522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=34522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}